Clinical Trial Detail

NCT ID NCT01767454
Title Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors GlaxoSmithKline
Indications

melanoma

Therapies

Dabrafenib + Ipilimumab + Trametinib

Dabrafenib + Ipilimumab

Age Groups: adult

Additional content available in CKB BOOST